Thu, Dec 12, 2024
Concord Biotech Ltd on Thursday said it has invested USD 10 lakh (nearly Rs 85 crore) in US-based Palvella Therapeutics, Inc with an aim to establish a partnership to manufacture and commercialise 'Qtorin', a drug used to treat serious and rare genetic skin diseases.
More >
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
